Literature DB >> 24768948

Clinical, molecular, and T cell subset analyses in a small cohort of Chinese patients with hyper-IgM syndrome type 1.

Wen-Jing Tang1, Yun-Fei An1, Rong-Xin Dai1, Qing-Hong Wang1, Li-Ping Jiang1, Xue-Mei Tang1, Xi-Qiang Yang1, Jie Yu1, Wen-Wei Tu2, Xiao-Dong Zhao3.   

Abstract

Type 1 hyper-IgM syndrome (HIGM1) is a rare primary immunodeficiency disease caused by mutations in the CD40L gene. Patients often present with recurrent infections and autoimmune manifestations. We investigated the clinical and molecular characteristics of HIGM1 in thirteen patients from the Chinese mainland and examined the proportion of CD4(+)CD25(+)FoxP3(+)Treg, Th17, and Th1 cells in the peripheral blood. We identified ten distinct CD40L mutations in eleven patients: one missense mutation, one nonsense mutation, one insertion mutation (in frame), and seven deletions. Six of these mutations were novel. We observed the percentage of Tregs in the peripheral blood of HIGM1 patients decreased markedly compared with that in healthy controls, but no statistically significant differences was found in the percentages of Th17 and Th1. The identified mutations reflect the heterogeneity of the CD40L gene in HIGM1. Precise genetic diagnosis of HIGM1 will enable appropriate therapeutic interventions, reliable detection of carriers, and genetic counseling. Skewed Treg, Th17/Treg, and Th1/Treg profiles may be associated with immune responses to autoimmunity or infection, which requires replication in larger studies.
Copyright © 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD40L; HIGM1; Th1; Th17; Treg

Mesh:

Substances:

Year:  2014        PMID: 24768948     DOI: 10.1016/j.humimm.2014.04.014

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  4 in total

1.  CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics.

Authors:  Tábata Takahashi França; Lucila Akune Barreiros; Ranieri Coelho Salgado; Sarah Maria da Silva Napoleão; Lillian Nunes Gomes; Janáira Fernandes Severo Ferreira; Carolina Prando; Cristina Worm Weber; Regina Sumiko Watanabe Di Gesu; Cecilia Montenegro; Carolina Sanchez Aranda; Gisele Kuntze; Aidé Tamara Staines-Boone; Edna Venegas-Montoya; Juan Carlos Aldave Becerra; Liliana Bezrodnik; Daniela Di Giovanni; Ileana Moreira; Gisela Analia Seminario; Andrea Cecilia Gómez Raccio; Mayra de Barros Dorna; Nelson Augusto Rosário-Filho; Herberto Jose Chong-Neto; Elisa de Carvalho; Milena Baptistella Grotta; Julio Cesar Orellana; Miguel Garcia Dominguez; Oscar Porras; Laura Sasia; Karina Salvucci; Emilio Garip; Luiz Fernando Bacarini Leite; Wilma Carvalho Neves Forte; Fernanda Pinto-Mariz; Ekaterini Goudouris; María Enriqueta Nuñez Nuñez; Magdalena Schelotto; Laura Berrón Ruiz; Diana Inés Liberatore; Hans D Ochs; Otavio Cabral-Marques; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2022-01-04       Impact factor: 8.317

2.  [Clinical and immunological profile of 15 Moroccan patients with Hyper IgM syndrome].

Authors:  Hind Ouair; Ibtihal Benhsaien; Leila Jeddane; Jalila El Bakkouri; Naima Elhafidi; Noureddine Rada; Jilali Najib; Fatima Ailal; Hanane Salih Alj; Ahmed Aziz Bousfiha
Journal:  Pan Afr Med J       Date:  2017-04-19

3.  Circulating Follicular Helper and Follicular Regulatory T Cells Are Severely Compromised in Human CD40 Deficiency: A Case Report.

Authors:  Maria Pia Cicalese; Jolanda Gerosa; Manuela Baronio; Davide Montin; Francesco Licciardi; Annarosa Soresina; Rosa Maria Dellepiane; Maurizio Miano; Lucia Augusta Baselli; Stefano Volpi; Carlo Dufour; Alessandro Plebani; Alessandro Aiuti; Vassilios Lougaris; Georgia Fousteri
Journal:  Front Immunol       Date:  2018-08-06       Impact factor: 7.561

4.  Clinical features and genetic analysis of 20 Chinese patients with X-linked hyper-IgM syndrome.

Authors:  Lin-Lin Wang; Wei Zhou; Wei Zhao; Zhi-Qing Tian; Wei-Fan Wang; Xiao-Fang Wang; Tong-Xin Chen
Journal:  J Immunol Res       Date:  2014-08-20       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.